How large is the HSV testing market?

The market valuation of HSV testing is estimated at USD 712.48 million in 2027.

What are the growth projections for the HSV testing industry?

HSV Testing Market size was valued at USD 675.98 million in 2026 and is anticipated to grow at a 6.36% CAGR from 2027 to 2036, crossing USD 1.25 billion by 2036.

How are diagnostic technology advancements accelerating HSV testing adoption?

Molecular diagnostics, rapid testing, laboratory automation, and improved sample processing are enhancing testing accuracy, efficiency, and accessibility, encouraging broader adoption across healthcare environments and patient settings.

How is healthcare infrastructure expansion influencing HSV testing demand in emerging markets?

Investments in laboratories, screening facilities, community health programs, and decentralized testing are improving diagnostic access, while integration with primary and sexual health services supports wider testing adoption.

Why do combined HSV-1/HSV-2 tests dominate the HSV testing market?

Combined HSV-1/HSV-2 tests held a 51.89% revenue share in 2026, offering broader diagnostic assessment when the viral type is uncertain and supporting more informed clinical evaluation and patient management.

How could point-of-care testing reshape purchasing priorities in the HSV testing market?

Point-of-care tests are expected to grow fastest as healthcare providers prioritize rapid diagnostic assessment, reduced laboratory-processing delays, decentralized testing access, and more efficient clinical decision-making.

What supports North America's leadership in the HSV testing market?

North America leads through established healthcare infrastructure, accessible clinical laboratories, growing sexual health awareness, and wider availability of molecular diagnostics and serological testing for accurate HSV identification.

Why is Asia Pacific expected to grow fastest in the HSV testing market?

Asia Pacific is the fastest-growing region, driven by improving diagnostic infrastructure, rising healthcare expenditure, greater STI awareness, and expanding access to modern laboratory testing and molecular diagnostic technologies.

Who holds a significant market share in the HSV testing landscape?

Prominent players in the HSV testing market include Roche Diagnostics (Switzerland), Abbott (USA), Hologic (USA), Cepheid / Danaher (USA), Qiagen (Netherlands), Thermo Fisher Scientific (USA), Becton Dickinson (USA), Bio-Rad Laboratories (USA), Seegene Inc. (South Korea), Siemens Healthineers (Germany).